Apremilast for the treatment of moderate-to-severe psoriasis: Real-world data from the Czech Republic BIOREP Registry

Kojanova M^a, Fialova J^a, Cetkovska P^b, Gkalpakiotis S^c, Machovcova A^d, Arenberger P^c, Stork J^a, Dolezal T^e, Turkova B^e, and the BIOREP study group

aDepartment of Dermatovenereology, First Faculty of Medicine in Pilsen, Charles University, Czech Republic; Department of Dermatovenereology, First Faculty of Medicine, and General University, Czech Republic; Department of Dermatovenereology, Third Faculty of Medicine, and General University, Czech Republic; Department of Dermatovenereology, Faculty of Medicine in Pilsen, Charles University, Czech Republic; Department of Dermatovenereology, Faculty of Medicine, and General University, Czech Republic; Department of Dermatovenereology, Faculty of Medicine, and General University, Czech Republic; Department of Dermatovenereology, Faculty of Medicine and General University, Czech Republic; Department of Dermatovenereology, Faculty of Medicine, and General University, Czech Republic; Department of Dermatovenereology, Faculty of Medicine, and General University, Czech Republic; Department of Dermatovenereology, Faculty of Medicine, and General University, Czech Republic; Department of Dermatovenereology, Faculty of Medicine, and General University, Czech Republic; Department of Dermatovenereology, Faculty of Medicine, and General University, Czech Republic; Department of Dermatovenereology, Faculty of Medicine, and General University, Czech Republic; Department of Dermatovenereology, Faculty of Medicine, and General University, Czech Republic; Department of Dermatovenereology, Faculty of Medicine, and General University, Czech Republic; Department of Dermatovenereology, Faculty of Medicine, and General University, Czech Republic; Department of Dermatovenereology, Faculty of Medicine, and General University, Czech Republic; Department of Dermatovenereology, Czech Republic; D Charles University and Kralovske Vinohrady University Hospital, Prague, Czech Republic; dMotol University Hospital, Prague, Czech Republic; dMotol University Hospital, Prague, Czech Republic.

INTRODUCTION

- Apremilast is an oral non-biological phosphodiesterase-4 inhibitor BIOREP is a national registry of patients with inflammatory skin The study included 349 apremilast patients with moderate-to-severe and has been approved for the treatment of moderate-to-severe plaque psoriasis; however, real-life evidence is still limited
- The aim of this study was to evaluate apremilast treatment in the real-world setting by analyzing data from the Czech Republic BIOREP Registry.

Table 1. Baseline characteristics

Age (years) Age at the time of diagnosis Age at the time of initiation of apremilast Duration of psoriasis (years) Duration from diagnosis to the initiation of apremilast Family history of psoriasis BMI (kg/m²) BMI category Underweight (<18.5) Normal (18.5−24.99) Overweight (25−29.99) Overweight (25−29.99) Obese (≥30) Psoriatic arthritis At least one comorbidity Selected comorbidities Hypertension Dyslipidemia Diabetes mellitus Depression Malignancy Smokers Ex-smokers Previous systemic therapy Phototherapy Methotrexate Retinoid Cyclosporine Other Previous biologic therapy (Yes) Anti-TNF IL-12/23 IL-17 IL-12/23 IL-17 IL-12/3 IL-15 IS-5 IL-17 IL-16 IL-17 IL-16 IL-17 IL-17 IL-16 IL-17 IL-		N/Mean	%/SD
Age (years) Age at the time of diagnosis Age at the time of initiation of apremilast Duration of psoriasis (years) Duration from diagnosis to the initiation of apremilast Family history of psoriasis BMI (kg/m²) BMI category Underweight (<18.5) Normal (18.5−24.99) Obese (≥30) Psoriatic arthritis At least one comorbidity Selected comorbidities Hypertension Dyslipidemia Diabetes mellitus Depression Malignancy Smokers Ex-smokers Previous systemic therapy Phototherapy Methotrexate Retinoid Cyclosporine Other Previous biologic therapy (Yes) Anti-TNF IL-12/23 IL-17 IL-12/23 IL-17 IL-12/23 IL-17 IL-12/23 IL-17 IL-12/3 IS-5. IS-1. IS-3.	Number of patients	349	
Age at the time of diagnosis Age at the time of initiation of apremilast Duration of psoriasis (years) Duration from diagnosis to the initiation of apremilast Duration from diagnosis to the initiation of apremilast Family history of psoriasis BMI (kg/m²) BMI category Underweight (<18.5) Normal (18.5−24.99) Overweight (25−29.99) Overweight (25−29.99) Overweight (25−29.99) Psoriatic arthritis At least one comorbidity Selected comorbidites Hypertension Dyslipidemia Diabetes mellitus Depression Malignancy Smokers Ex-smokers Previous systemic therapy Phototherapy Phototherapy Phototherapy Phototherapy Phototherapy Phototherapy Other Previous biologic therapy (Yes) Anti-TNF U-12/23 IL-17 IL-12/23 IL-17 IL-12/23 IL-17 IL-12/3 IL-17 IL-12/3 IL-17 IL-13 I 0.3% PASI	Men	192	55.0%
Age at the time of initiation of apremilast Duration of psoriasis (years) Duration from diagnosis to the initiation of apremilast Family history of psoriasis BMI (kg/m²) BMI category Underweight (<18.5) Normal (18.5−24.99) Overweight (25−29.99) Overweight (25−29.99) Overweight (25−29.99) Psoriatic arthritis At least one comorbidity Selected comorbidities Hypertension Dyslipidemia Diabetes mellitus Depression Malignancy Smokers Ex-smokers Previous systemic therapy Phototherapy Methotrexate Retinoid Cyclosporine Other Previous biologic therapy (Yes) Anti-TNF L-12/23 L-17 L-23 PASI 15.0 15.1 14.3 15.5 15.1 15.1 15.2 15.1 15.1 15.2 15.1 15.1 15.2 15.2 15.1 15.1 15.2 15.2 15.1 15.1 15.2 15.2 15.1 15.1 15.2 15.2 15.1 15.1 15.2 15.2 15.1 15.1 15.2 15.2 15.1 15.1 15.2 15.2 15.1 15.1 15.2 15.1 15.1 15.2 15.2 15.1 15.1 15.2 15.1 15.1 15.2 15.1 15.1 15.2 15.1 15.1 15.1 15.2 15.1 15.1 15.2 15.1 15.1 15.1 15.2 15.1 15.1 15.2 15.1 15.1 15.2 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1	Age (years)	53.4	14.3
apremilast Duration of psoriasis (years) Duration from diagnosis to the initiation of apremilast Family history of psoriasis BMI (kg/m²) BMI category Underweight (<18.5) Normal (18.5−24.99) Obese (≥30) Psoriatic arthritis At least one comorbidity Diabetes mellitus Depression Dyslipidemia Diabetes mellitus Depression Malignancy Smokers Ex-smokers Previous systemic therapy Phototherapy Methotrexate Retinoid Cyclosporine Other Previous biologic therapy (Yes) Anti-TNF IL-12/23 IL-17 IL-12/23 IL-17 IL-12/23 PASI PASI 13.4 35.4 15.0 15.1 15.1 15.1 15.1 15.1 15.1 15.2 15.1 15.1 15.2 15.1 15.1 15.2 15.1 15.1 15.1 15.2 15.1 15.1 15.1 15.2 15.1 15.1 15.1 15.2 15.1 15.1 15.2 15.1 15.1 15.2 15.1 15.1 15.1 15.2 15.1 15.1 15.1 15.2 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1 15.1	Age at the time of diagnosis	28.2	15.9
Duration from diagnosis to the initiation of apremilast 23.2 15.0 Family history of psoriasis 134 38.4% BMI (kg/m²) 29.3 6.2 BMI category 29.3 6.2 Underweight (<18.5)		51.4	14.3
initiation of apremilast 23.2 15.0 Family history of psoriasis 134 38.4% BMI (kg/m²) 29.3 6.2 BMI category 29.3 6.2 Underweight (<18.5)	Duration of psoriasis (years)	25.2	15.1
Family history of psoriasis BMI (kg/m²) BMI category Underweight (<18.5) Normal (18.5–24.99) Overweight (25–29.99) Obese (≥30) Psoriatic arthritis At least one comorbidity Selected comorbidities Hypertension Dyslipidemia Diabetes mellitus Depression Malignancy Smokers Previous systemic therapy Phototherapy Phototherapy Attenary Phototherapy Previous biologic therapy (Yes) Anti-TNF IL-12/23 IL-17 IL-23 PASI BMI category 29.3 4 1.1% 1.1% 1.1% 1.1% 1.1% 1.1% 1.1% 1.1% 1.1% 1.1% 1.1% 1.1% 1.1% 1.1% 1.1% 1.1% 1.1% 1.1% 1.1% 1.1% 1.1% 1.1% 1.1% 1.1% 1.1% 1.1% 1.1% 1.1% 1.1% 1.1% 1.1% 1.1% 1.1% 1.1% 1.1% 1.1% 1.1% 1.1% 1.1% 1.1% 1.1% 1.1% 1.1% 1.1% 1.1% 1.1% 1.1% 1.1% 1.1% 1.1% 1.1% 1.1% 1.1% 1.1% 1.1% 1.1% 1.1% 1.1% 1.1% 1.1% 1.1% 1.1% 1.1% 1.1% 1.1% 1.1% 1.1% 1.1% 1.1% 1.1% 1.1% 1.1% 1.1% 1.1% 1.1% 1.1% 1.1% 1.1% 1.1% 1.1% 1.1% 1.1% 1.1% 1.1% 1.1% 1.1% 1.1% 1.1% 1.1% 1.1% 1.1% 1.1% 1.1% 1.1% 1.1% 1.1% 1.1% 1.1% 1.1% 1.1% 1.1% 1.1% 1.1% 1.1% 1.1% 1.1% 1.1% 1.1% 1.1% 1.1% 1.1% 1.1% 1.1% 1.1% 1.1% 1.1% 1.1% 1.1% 1.1% 1.1% 1.1% 1.1% 1.1% 1.1% 1.1% 1.1% 1.1% 1.1% 1.1% 1.1% 1.1% 1.1% 1.1% 1.1% 1.1% 1.1% 1.1% 1.1% 1.1% 1.1% 1.1% 1.1% 1.1% 1.1% 1.1% 1.1% 1.1% 1.1% 1.1% 1.1% 1.1% 1.1% 1.1% 1.1% 1.1% 1.1% 1.1% 1.1% 1.1% 1.1% 1.1% 1.1% 1.1% 1.1% 1.1% 1.1% 1.1% 1.1% 1.1% 1.1% 1.1% 1.1% 1.1% 1.1% 1.1% 1.1% 1.1% 1.1% 1.1% 1.1% 1.1% 1.1% 1.1% 1.1% 1.1% 1.1% 1.1% 1.1% 1.1% 1.1% 1.1% 1.1% 1.1% 1.1% 1.1% 1.1% 1.1% 1.1% 1.1% 1.1% 1.1% 1.1% 1.1% 1.1% 1.1% 1.1% 1.1% 1.1% 1.1% 1.1% 1.1% 1.1% 1.1% 1.1% 1.1% 1.1% 1.1% 1.1% 1.1% 1.1% 1.1% 1.1% 1.1% 1.1% 1.1% 1.1% 1.1% 1.1% 1.1% 1.1% 1.1% 1.1% 1.1% 1.1% 1.1% 1.1% 1.1% 1.1% 1.1% 1.1% 1.1% 1.1% 1.1% 1.1% 1.1% 1.1% 1.1% 1.1% 1.1% 1.1% 1.1% 1.1% 1.1% 1.1% 1.1% 1.1% 1.1% 1.1% 1.1% 1.1% 1.1% 1.1% 1.1% 1.1% 1.		23.2	15.0
BMI (kg/m²) 29.3 6.2 BMI category Underweight (<18.5) 4 1.1% Normal (18.5–24.99) 89 25.5% Overweight (25–29.99) 113 32.4% Obese (≥30) 143 41.0% Psoriatic arthritis 88 25.2% At least one comorbidity 237 67.9% Selected comorbidities Hypertension 124 35.5% Dyslipidemia 93 26.6% Diabetes mellitus 61 17.5% Depression 20 5.7% Malignancy 45 12.0% Smokers 116 33.2% Ex-smokers 67 19.2% Previous systemic therapy Phototherapy 245 70.2% Methotrexate 282 80.8% Retinoid 195 55.9% Cyclosporine 102 29.2% Other 28 8.0% Previous biologic therapy (Yes) 47 13.5% Anti-TNF 20 5.7% IL-12/23 12 3.4% IL-17 14 4.0% IL-23 1 0.3% PASI 15.5 6.2	· · · · · · · · · · · · · · · · · · ·	134	38.4%
Underweight (<18.5)		29.3	6.2
Normal (18.5–24.99) 89 25.5% Overweight (25–29.99) 113 32.4% Obese (≥30) 143 41.0% Psoriatic arthritis 88 25.2% At least one comorbidity 237 67.9% Selected comorbidities 124 35.5% Hypertension 124 35.5% Dyslipidemia 93 26.6% Diabetes mellitus 61 17.5% Depression 20 5.7% Malignancy 45 12.0% Smokers 116 33.2% Ex-smokers 67 19.2% Previous systemic therapy 245 70.2% Methotrexate 282 80.8% Retinoid 195 55.9% Cyclosporine 102 29.2% Other 28 8.0% Previous biologic therapy (Yes) 47 13.5% Anti-TNF 20 5.7% IL-12/23 12 3.4% IL-12/23 12 3.4% IL-23 1 0.3%	BMI category		
Overweight (25–29.99) 113 32.4% Obese (≥30) 143 41.0% Psoriatic arthritis 88 25.2% At least one comorbidity 237 67.9% Selected comorbidities 124 35.5% Hypertension 124 35.5% Dyslipidemia 93 26.6% Diabetes mellitus 61 17.5% Depression 20 5.7% Malignancy 45 12.0% Smokers 116 33.2% Ex-smokers 67 19.2% Previous systemic therapy 245 70.2% Methotrexate 282 80.8% Retinoid 195 55.9% Cyclosporine 102 29.2% Other 28 8.0% Previous biologic therapy (Yes) 47 13.5% Anti-TNF 20 5.7% IL-12/23 12 3.4% IL-17 14 4.0% IL-23 1 0.3% PASI 15.5 6.2	Underweight (<18.5)	4	1.1%
Obese (≥30) 143 41.0% Psoriatic arthritis 88 25.2% At least one comorbidity 237 67.9% Selected comorbidities 124 35.5% Hypertension 124 35.5% Dyslipidemia 93 26.6% Diabetes mellitus 61 17.5% Depression 20 5.7% Malignancy 45 12.0% Smokers 116 33.2% Ex-smokers 67 19.2% Previous systemic therapy 245 70.2% Methotrexate 282 80.8% Retinoid 195 55.9% Cyclosporine 102 29.2% Other 28 8.0% Previous biologic therapy (Yes) 47 13.5% Anti-TNF 20 5.7% IL-12/23 12 3.4% IL-17 14 4.0% IL-23 1 0.3% PASI 15.5 6.2	Normal (18.5–24.99)	89	25.5%
Psoriatic arthritis 88 25.2% At least one comorbidity 237 67.9% Selected comorbidities 124 35.5% Hypertension 124 35.5% Dyslipidemia 93 26.6% Diabetes mellitus 61 17.5% Depression 20 5.7% Malignancy 45 12.0% Smokers 116 33.2% Ex-smokers 67 19.2% Previous systemic therapy 245 70.2% Methotrexate 282 80.8% Retinoid 195 55.9% Cyclosporine 102 29.2% Other 28 8.0% Previous biologic therapy (Yes) 47 13.5% Anti-TNF 20 5.7% IL-12/23 12 3.4% IL-17 14 4.0% IL-23 1 0.3% PASI 15.5 6.2	Overweight (25-29.99)	113	32.4%
Psoriatic arthritis 88 25.2% At least one comorbidity 237 67.9% Selected comorbidities 124 35.5% Hypertension 124 35.5% Dyslipidemia 93 26.6% Diabetes mellitus 61 17.5% Depression 20 5.7% Malignancy 45 12.0% Smokers 116 33.2% Ex-smokers 67 19.2% Previous systemic therapy 245 70.2% Methotrexate 282 80.8% Retinoid 195 55.9% Cyclosporine 102 29.2% Other 28 8.0% Previous biologic therapy (Yes) 47 13.5% Anti-TNF 20 5.7% IL-12/23 12 3.4% IL-17 14 4.0% IL-23 1 0.3% PASI 15.5 6.2	,	143	41.0%
Selected comorbidities Hypertension 124 35.5% Dyslipidemia 93 26.6% Diabetes mellitus 61 17.5% Depression 20 5.7% Malignancy 45 12.0% Smokers 116 33.2% Ex-smokers 67 19.2% Previous systemic therapy 245 70.2% Methotrexate 282 80.8% Retinoid 195 55.9% Cyclosporine 102 29.2% Other 28 8.0% Previous biologic therapy (Yes) 47 13.5% Anti-TNF 20 5.7% IL-12/23 12 3.4% IL-17 14 4.0% IL-23 1 0.3% PASI 15.5 6.2		88	25.2%
Selected comorbidities Hypertension 124 35.5% Dyslipidemia 93 26.6% Diabetes mellitus 61 17.5% Depression 20 5.7% Malignancy 45 12.0% Smokers 116 33.2% Ex-smokers 67 19.2% Previous systemic therapy 245 70.2% Methotrexate 282 80.8% Retinoid 195 55.9% Cyclosporine 102 29.2% Other 28 8.0% Previous biologic therapy (Yes) 47 13.5% Anti-TNF 20 5.7% IL-12/23 12 3.4% IL-17 14 4.0% IL-23 1 0.3% PASI 15.5 6.2	At least one comorbidity	237	67.9%
Dyslipidemia 93 26.6% Diabetes mellitus 61 17.5% Depression 20 5.7% Malignancy 45 12.0% Smokers 116 33.2% Ex-smokers 67 19.2% Previous systemic therapy 245 70.2% Methotrexate 282 80.8% Retinoid 195 55.9% Cyclosporine 102 29.2% Other 28 8.0% Previous biologic therapy (Yes) 47 13.5% Anti-TNF 20 5.7% IL-12/23 12 3.4% IL-17 14 4.0% IL-23 1 0.3% PASI 15.5 6.2	·		
Diabetes mellitus 61 17.5% Depression 20 5.7% Malignancy 45 12.0% Smokers 116 33.2% Ex-smokers 67 19.2% Previous systemic therapy 245 70.2% Methotrexate 282 80.8% Retinoid 195 55.9% Cyclosporine 102 29.2% Other 28 8.0% Previous biologic therapy (Yes) 47 13.5% Anti-TNF 20 5.7% IL-12/23 12 3.4% IL-17 14 4.0% IL-23 1 0.3% PASI 15.5 6.2	Hypertension	124	35.5%
Depression 20 5.7% Malignancy 45 12.0% Smokers 116 33.2% Ex-smokers 67 19.2% Previous systemic therapy 245 70.2% Phototherapy 245 70.2% Methotrexate 282 80.8% Retinoid 195 55.9% Cyclosporine 102 29.2% Other 28 8.0% Previous biologic therapy (Yes) 47 13.5% Anti-TNF 20 5.7% IL-12/23 12 3.4% IL-17 14 4.0% IL-23 1 0.3% PASI 15.5 6.2	Dyslipidemia	93	26.6%
Malignancy 45 12.0% Smokers 116 33.2% Ex-smokers 67 19.2% Previous systemic therapy 245 70.2% Phototherapy 245 70.2% Methotrexate 282 80.8% Retinoid 195 55.9% Cyclosporine 102 29.2% Other 28 8.0% Previous biologic therapy (Yes) 47 13.5% Anti-TNF 20 5.7% IL-12/23 12 3.4% IL-17 14 4.0% IL-23 1 0.3% PASI 15.5 6.2	Diabetes mellitus	61	17.5%
Smokers 116 33.2% Ex-smokers 67 19.2% Previous systemic therapy 245 70.2% Phototherapy 245 70.2% Methotrexate 282 80.8% Retinoid 195 55.9% Cyclosporine 102 29.2% Other 28 8.0% Previous biologic therapy (Yes) 47 13.5% Anti-TNF 20 5.7% IL-12/23 12 3.4% IL-17 14 4.0% IL-23 1 0.3% PASI 15.5 6.2	Depression	20	5.7%
Ex-smokers 67 19.2% Previous systemic therapy 245 70.2% Phototherapy 245 70.2% Methotrexate 282 80.8% Retinoid 195 55.9% Cyclosporine 102 29.2% Other 28 8.0% Previous biologic therapy (Yes) 47 13.5% Anti-TNF 20 5.7% IL-12/23 12 3.4% IL-17 14 4.0% IL-23 1 0.3% PASI 15.5 6.2	Malignancy	45	12.0%
Previous systemic therapy 245 70.2% Phototherapy 245 70.2% Methotrexate 282 80.8% Retinoid 195 55.9% Cyclosporine 102 29.2% Other 28 8.0% Previous biologic therapy (Yes) 47 13.5% Anti-TNF 20 5.7% IL-12/23 12 3.4% IL-17 14 4.0% IL-23 1 0.3% PASI 15.5 6.2	Smokers	116	33.2%
Phototherapy 245 70.2% Methotrexate 282 80.8% Retinoid 195 55.9% Cyclosporine 102 29.2% Other 28 8.0% Previous biologic therapy (Yes) 47 13.5% Anti-TNF 20 5.7% IL-12/23 12 3.4% IL-17 14 4.0% IL-23 1 0.3% PASI 15.5 6.2	Ex-smokers	67	19.2%
Phototherapy 245 70.2% Methotrexate 282 80.8% Retinoid 195 55.9% Cyclosporine 102 29.2% Other 28 8.0% Previous biologic therapy (Yes) 47 13.5% Anti-TNF 20 5.7% IL-12/23 12 3.4% IL-17 14 4.0% IL-23 1 0.3% PASI 15.5 6.2	Previous systemic therapy		
Retinoid19555.9%Cyclosporine10229.2%Other288.0%Previous biologic therapy (Yes)4713.5%Anti-TNF205.7%IL-12/23123.4%IL-17144.0%IL-2310.3%PASI15.56.2		245	70.2%
Cyclosporine 102 29.2% Other 28 8.0% Previous biologic therapy (Yes) 47 13.5% Anti-TNF 20 5.7% IL-12/23 12 3.4% IL-17 14 4.0% IL-23 1 0.3% PASI 15.5 6.2	Methotrexate	282	80.8%
Other 28 8.0% Previous biologic therapy (Yes) 47 13.5% Anti-TNF 20 5.7% IL-12/23 12 3.4% IL-17 14 4.0% IL-23 1 0.3% PASI 15.5 6.2	Retinoid	195	55.9%
Other 28 8.0% Previous biologic therapy (Yes) 47 13.5% Anti-TNF 20 5.7% IL-12/23 12 3.4% IL-17 14 4.0% IL-23 1 0.3% PASI 15.5 6.2	Cyclosporine	102	29.2%
Anti-TNF 20 5.7% IL-12/23 12 3.4% IL-17 14 4.0% IL-23 1 0.3% PASI 15.5 6.2	, , ,	28	8.0%
Anti-TNF 20 5.7% IL-12/23 12 3.4% IL-17 14 4.0% IL-23 1 0.3% PASI 15.5 6.2	Previous biologic therapy (Yes)	47	13.5%
IL-12/23 12 3.4% IL-17 14 4.0% IL-23 1 0.3% PASI 15.5 6.2		20	
IL-17 14 4.0% IL-23 1 0.3% PASI 15.5 6.2			
IL-23 1 0.3% PASI 15.5 6.2	•		
PASI 15.5 6.2		1	
		15.5	
DLQI 14.9 6.3	DLQI	14.9	6.3

Values are n (%) of patients or mean (± SD); BMI, Body Mass Index

PASI, Psoriasis Areaand Severity Index; DLQI, Dermatology Life Quality Index

MATERIAL AND METHODS

- diseases (psoriasis, hidradenitis suppurativa and atopic dermatitis) treated with targeted therapy in the Czech Republic. The registry was established in 2005 to monitor the long-term efficacy and safety of targeted treatment of psoriasis.
- We analyzed the cohort of patients on apremilast therapy until January 2023.





Figure 3. DLQI improvement

Figure 4. Drug survival C) By sex


Time (months)


Figure 2. PASI improvement




D) By PsA at baseline (yes/no)

D) Time to discontinuation of treatment by psoriatic arthritis





PsA + No + Yes




RESULTS

- psoriasis.
- Patients were predominantly male (55.0%); mean time from diagnosis to initiation of apremilast therapy was 23.2 years. Psoriatic arthritis was present in 25.2% of patients. Before starting treatment, patients were most often treated with methotrexate (80.8%) and/or phototherapy (70.2%), and a total of 13.5% of patients were treated with biologics. (Table 1)
- The mean PASI at baseline was 15.5 (SD 6.2) and was decreased to 2.5 (SD 3.0), 2.4 (SD 3.1), 1.9 (SD 2.8) and 1.1 (SD 1.1) after 12, 24, 36 and 48 months. Similarly, a decrease in DLQI was observed at 12 months from 14.9 (SD 6.3) to 2.6 (SD 3.0) with average values from 3.1 to 1.3 until 48 months. At 4, 12, 24, 36 and 48 months of treatment, a total of 87.8%, 92.5%, 92.5%, 94.4% and 100.0% of patients achieved PASI 50; 59.7%, 68.8%, 80.0%, 83.3% and 90.0% of patients reached PASI 75; 24.9%, 50.5%, 45.0%, 61.1% and 70.0% achieved PASI 90, and 12.2%, 25.8%, 20.0%, 27.8% and 30.0% of patients achieved PASI 100, respectively. (Table 1, Figure 1-3)
- The therapy was discontinued in 69.4% treatment series (loss of effectiveness in 51.6%, adverse events in 6.5%). (Table 2)
- Predicted drug survival probability at 12, 24, 36 and 48 months of treatment was 42.9%, 19.6%, 10.8% and 8.3%, respectively. Patients with psoriatic arthritis had on average 33.1% (95% CI 8.6-51.0%) lower risk of discontinuation apremilast treatment compared to patients without PsA, no difference in survival probability was found according to naivety, gender, or obesity. (Figure 4. A-E)


B) Naïve/experienced

B) Time to discontinuation of treatment by naivity

Figure 4. Drug survival A) All subjects



E) By obesity



E) Time to discontinuation of treatment by obesity

p = 0.37





Figure 1. PASI improvement (50, 75, 90, 100)



DISCUSSION

In this analysis of real-world data, patients initiating apremilast therapy had severe disease with a high impact on quality of life at baseline. Data indicate high rates of clearance and improvement in quality of life in patients with psoriasis on apremilast therapy. Our analysis fills the gap of efficacy, safety, and survival probability for apremilast treatment from real clinical practice.

Table 2. Discontinuation of therapy

N	%
182	51.6%
24	6.8%
18	5.1%
8	2.3%
3	0.8%
2	0.6%
3	0.8%
1	0.3%
1	0.3%
3	0.8%
245	69.4%
	182 24 18 8 3 2 3 1 1 1 3

Acknowledgements

BIOREP Study Group Members: Zdenek Antal, Jirina Bartonova, Linda Blahova, Petra Brodska, Petr Bohac, Hana Buckova, Martin Cetkovsky, Jana Cadova, Dominika Diamantova, Magdalena Dobiasova, Hana Duchkova, Olga Filipovska, Jana Földesova, Petra Gkalpakioti, Martina Grycova, Jiri Horazdovsky, Eva Horka, Katerina Hrazdirova, Eduard Hrncir, Jana Chlebkova, Jaromira Janku, Lucie Jaresova, Renata Kopova, Dora Kovandova, Silvie Krchova, Lenka Kulmanova, Natalie Kunesova, Iva Lomicova, Romana Machackova, Alena Machovcova, Hana Malikova, Martina Matzenauer, Miroslav Necas, Helena Nemcova, Radka Neumannova, Michaela Novakova, Jitka Osmerova, Veronika Pallova, Lucie Petru, Blanka Pinkova, Zuzana Plzakova, Marie Policarova, Tomas Pospisil, Filip Rob, Miloslav Salavec, Marie Selerova, Veronika Slonkova, Ivana Strouhalova, David Stuchlik, Alena Stumpfova, Jaroslav Sevcik, Jan Sternbersky, Katerina Svarcova, Katerina Tepla, Martin Tichy, Hana Tomkova, Yvetta Vantuchova, Ivana Vejrova, Iva Zampachova.

0.75

0.50

0.25

p = 0.19

Number at risk